Sjögren’s Syndrome (SS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Sjögren syndrome (SS) is a gradually progressing autoimmune disorder with various organ-specific and systemic symptoms. In SS patients, B-cell activation is consistently observed, leading to the infiltration of B and T cells into target organs, resulting in damage. The typical SS patient, most commonly perimenopausal women, experiences reduced lacrimal and salivary gland function symptoms. Common manifestations include dry mouth (xerostomia), dry eyes (keratoconjunctivitis sicca), and enlargement of the parotid glands. The oral dryness experienced by SS patients can significantly impact their quality of life, interfering with basic daily activities like eating, speaking, and sleeping. The reduction in salivary volume also reduces saliva's natural antibacterial properties, increasing the risk of infections, tooth decay, and periodontal disease. SS patients often complain of ocular discomfort, including itching, grittiness, soreness, and dryness, despite the outward appearance of normal eyes. The reduced tear secretion can lead to chronic irritation and damage to the corneal and bulbar conjunctival epithelium (keratoconjunctivitis sicca). Salivary gland swelling, initially unilateral but often becoming bilateral, can be either chronic or episodic. Sjögren syndrome can occur independently as primary SS or in conjunction with systemic autoimmune rheumatic diseases, referred to as secondary SS. Because SS symptoms may not manifest simultaneously, medical professionals, including physicians and dentists, may treat individual symptoms without recognizing the underlying systemic disease. The differential diagnosis of SS involves considering conditions and medications that can cause symptoms such as keratoconjunctivitis sicca, xerostomia, and parotid gland enlargement. Two FDA-approved drugs, Salagen (pilocarpine) and Evoxac (cevimeline), can increase saliva production and treat dry mouth in SS. The prevalence of SS varies significantly across different reports, with changes of up to tenfold noted between countries and within the same country.

 

·       Reported prevalence rates range from 0.1% to 4.8%. Worldwide, SS prevalence varies, with 320 cases in North America and 200 to 3,000 cases per 100,000 individuals in Northern and Southern Europe, respectively.

 

Thelansis’s “Sjögren’s Syndrome (SS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sjögren’s Syndrome (SS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Sjögren’s Syndrome (SS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Sjögren’s Syndrome (SS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Sjögren’s Syndrome (SS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Sjögren’s Syndrome (SS), Sjögren’s Syndrome (SS) market outlook, Sjögren’s Syndrome (SS) competitive landscape, Sjögren’s Syndrome (SS) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)